Novel anticoagulants for the prevention and treatment of venous thromboembolism
Review published in Wiener medizinische Wochenschrift (1946) (2003)
Abstract
Unfractionated heparin, low molecular weight heparin and vitamin K antagonists are anticoagulants currently used for the prevention and treatment of deep vein thrombosis and pulmonary embolism. Considerable limitations of these agents, such as a narrow therapeutic window, a variable dose response or lack of oral bioavailability, created the need for new anticoagulants. Numerous new compounds with different mechanisms of action have been developed and some have been already approved for clinical use. Quite recently, fondaparinux, an indirect anti-factor Xa inhibitor, has been licensed in Europe and in the US for prevention of VTE in patients undergoing hip or knee replacement surgery. In addition, lepirudin, a recombinant hirudin derivative, and the heparinoid danaparoid, have been approved in Austria for treatment of heparin-induced thrombocytopenia. Recombinant nematode anticoagulant protein c2, the orally available thrombin inhibitor ximelagatran and ART-123, a recombinant soluble thrombomodulin, are in advanced stages of clinical development. This article reviews mechanisms and sites of action, and the current state of preclinical and clinical research of these and various other agents with respect to the prevention and treatment of venous thromboembolism).
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Unfractionated heparin, low molecular weight heparin and vitamin K antagonists are anticoagulants currently used for the prevention and treatment of deep vein thrombosis and pulmonary embolism.
Por qué esto importa para la hirudoterapia
Esta revisión abarca anticoagulantes novedosos para la prevención y el tratamiento del tromboembolismo venoso, incluidos fondaparinux, lepirudina, danaparoide, ximelagatrán, la proteína anticoagulante recombinante c2 del nematodo y la trombomodulina soluble recombinante. El resumen indica que la lepirudina, descrita como un derivado recombinante de la hirudina, fue aprobada en Austria para el tratamiento de la trombocitopenia inducida por heparina, y describe los mecanismos y sitios de acción de estos agentes. Para el ámbito de ASH, existe relevancia a través del derivado farmacéutico de hirudina lepirudina, que se analiza como uno entre varios anticoagulantes novedosos. La advertencia es que el alcance de la revisión es amplio, no se aborda la hirudoterapia en vivo ni el secretoma nativo de la sanguijuela, y el resumen no describe el origen biológico de la hirudina.
Citación
Novel anticoagulants for the prevention and treatment of venous thromboembolism
Weltermann A et al. · Wiener medizinische Wochenschrift (1946), 2003
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026